Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Gates Foundation awards USF $5.45M for malaria research

Gates Foundation awards USF $5.45M for malaria research

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Executive wellness a legit corporate expense

Executive wellness a legit corporate expense

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

New way to stabilize proteins

New way to stabilize proteins

Lead exposure can lead to high blood pressure in pregnant women: Study

Lead exposure can lead to high blood pressure in pregnant women: Study

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Exposure to infections in early childhood can protect child from eczema later in life: Study

Exposure to infections in early childhood can protect child from eczema later in life: Study

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand announces acquisition of CyDex Pharmaceuticals

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

Wrigley launches school-based program to improve health, nutrition in school-age children

Wrigley launches school-based program to improve health, nutrition in school-age children

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Study evaluates Masimo SpHb's accuracy in monitoring low hemoglobin levels

Study evaluates Masimo SpHb's accuracy in monitoring low hemoglobin levels

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.